ARCHIVES

Phase III Custirsen/Docetaxel/Prednisone Trial Fails Primary Endpoint of Overall Survival

This article is from The Cancer Letter archive.

Vol. 37 No. 4 | April 25, 2014

Download PDF Visit The Full Archive

Related Articles

NCI Puts Aside Fear Of Brockovich Factor To Open New Web Site On Mortality Data.

April 20, 2001

Major Emphasis Switch; Outreach Core Support Ends In Favor Of Cancer Control Research

January 22, 1982

Three Geneticists Of “Knockout” Mice Fame Win Lasker Award For Basic Research.

September 28, 2001

NIH Describes Peer Review Process

July 12, 1996

NCAB Criticizes Coverage’ Of NCI Screening Statement

March 4, 1994

Broder Not Satisfied With Mortality STATS On Three Major Cancers

September 20, 1991